ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or “RegeneRx”) today announced that it has received a Notice of Allowance of a Canadian patent application for using Thymosin beta 4 (Tß4) and various fragments and other related peptides for inhibiting or reversing skin aging. The patent will expire in 2021.
Help employers find you! Check out all the jobs and post your resume.
